DLL3
DLL3 Informations sur la molécule
| Nom anglais | Delta-like protein 3 | Nombre de médicaments commercialisés | 1 |
| Nombre de médicaments cliniques | 30 | Alias de la cible | Delta-Like Protein 3，Delta3，Delta-Like 3，Drosophila Delta Homolog 3，SCDO1，Delta-Like 3 (Drosophila)，DLL3，Delta (Drosophila)-Like 3，Delta Like Canonical Notch Ligand 3 |
| Phase de R&D la plus avancée | Approved | ||
| Nom anglais | Delta-like protein 3 |
| Alias de la cible | Delta-Like Protein 3，Delta3，Delta-Like 3，Drosophila Delta Homolog 3，SCDO1，Delta-Like 3 (Drosophila)，DLL3，Delta (Drosophila)-Like 3，Delta Like Canonical Notch Ligand 3 |
| Nombre de médicaments commercialisés | 1 |
| Nombre de médicaments cliniques | 30 |
| Phase de R&D la plus avancée | Approved |
DLL3 Liste de produits
- Attribut
Protein (26)Cell (2)Cell Grade Beads (1)Kits (1)Beads (1)
- Bibliothèque de produits
En ligne (31)
- Espèces
Human (24)Cynomolgus (4)Rat (1)Rhesus macaque (1)Mouse (1)
- Étiquette
His Tag (19)- (6)His Tag & Avi Tag (2)Llama IgG Fc Tag (1)Fc Tag (1)Mouse IgG Fc Tag (2)
- Marqueur
Unconjugated (19)FITC Labeled (1)Biotin-labeled (3)PE Labeled (1)- (5)APC Labeled (1)AF647 Labeled (1)
| Numéro de produit | Espèces | Système d'expression | Description du produit | Structure protéique | Pureté | Caractéristiques | Pré-commande/Commande |
|---|---|---|---|---|---|---|---|
 Human | HEK293 | Human DLL3 Protein, His Tag, low endotoxin (Mass Spec & MALS verified) |  |  |  |  Ajouter au panier | |
 Mouse | HEK293 | Mouse DLL3 Protein, His Tag, low endotoxin (HPLC verified) | | | Ajouter au panier | ||
 Cynomolgus | HEK293 | Cynomolgus DLL3 Protein, His Tag (MALS verified) |  | | | Ajouter au panier | |
| Human | - | Human DLL3 ELISA Kit | Ajouter au panier | ||||
| Human | HEK293 | HEK293/Human DLL3 Stable Cell Line |  | Ajouter au panier | |||
| Human | HEK293 | Human DLL3 Protein, His Tag (HPLC verified) |  | | | Ajouter au panier | |
| Human | HEK293 | Human DLL3 (353-427) Protein, Mouse IgG2a Fc Tag, low endotoxin (MALS verified) |  | | | Ajouter au panier | |
| Human | HEK293 | Human DLL3 (353-465) Protein, Mouse IgG2a Fc Tag, low endotoxin |  | | | Ajouter au panier | |
| Human | HEK293 | Human DLL3 Protein, Llama IgG2b Fc Tag, low endotoxin |  | | | Ajouter au panier | |
| Human | HEK293 | Human DLL3 (27-215) Protein, Fc Tag (MALS verified) |  | | | Ajouter au panier |
Quantité totale31
- 1
- 2
- 3
- 4
DLL3Contexte de la molécule
Delta-like protein 3 (DLL3) is a transmembrane protein that belongs to the Delta/Serrate/Lag-2 (DSL) family of Notch ligands.May be required to divert neurons along a specific differentiation pathway. Plays a role in the formation of somite boundaries during segmentation of the paraxial mesoderm. DLL3 protein is expressed on the surface of tumor cells but not in normal adult tissues.
DLL3Alias de la molécule
Delta3,delta-like 3 (Drosophila),delta-like protein 3,DLL3,Pudgy,SCDO1,SCDO1delta3
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| Zocilurtatug pelitecan | ZL-1310; YL-212 | Phase 3 Clinical | Zai Lab (Shanghai) Co Ltd | Small Cell Lung Carcinoma; Solid tumours | Details |
| Obrixtamig | BI-764532; OBT620 | Phase 3 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Carcinoma, Neuroendocrine; Glioma; Neoplasms; Neuroendocrine Tumors; Small Cell Lung Carcinoma | Details |
| Alveltamig | ZG-006; ZG006 | Phase 3 Clinical | Gensun Biopharma Inc, Suzhou Zelgen Biopharmaceuticals Co Ltd | Carcinoma, Neuroendocrine; Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours | Details |
| 89Zr-DFO-SC16.56 | 89Zr-DFO-SC16.56 | Phase 2 Clinical | Memorial Sloan Kettering Cancer Center | Small Cell Lung Carcinoma | Details |
| Gocatamig | HPN-328; MK-6070; DS-3280 | Phase 2 Clinical | Harpoon Therapeutics | Carcinoma, Neuroendocrine; Small Cell Lung Carcinoma | Details |
| EB-DART-NK01 | EB-DART-NK01 | Phase 2 Clinical | Beijing Biotech | Small Cell Lung Carcinoma | Details |
| 4sCAR-DLL3 CAR-T Therapy (Shenzhen Geno-Immune Medical Institute) | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Glioblastoma; Melanoma | Details | |
| SHR-7787 | SHR-7787; SHR7787 | Phase 2 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Small Cell Lung Carcinoma; Solid tumours | Details |
| SHR-4849 | SHR-4849; SHR4849; IDE849; IDE-849 | Phase 2 Clinical | Jiangsu Hengrui Pharmaceutical Group Co Ltd | Carcinoma, Neuroendocrine; Small Cell Lung Carcinoma; Solid tumours | Details |
| DLL3-CAR-NK cells Therapy(Tianjin Medical University Cancer Institute and Hospital) | DLL3-CAR-NK cells | Phase 2 Clinical | Tianjin Medical University Cancer Institute And Hospital | Small Cell Lung Carcinoma | Details |
| Peluntamig | PT-217 | Phase 2 Clinical | Phanes Therapeutics Inc | Carcinoma, Neuroendocrine; Neuroendocrine Carcinoma of Lung; Prostatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours | Details |
| ML-261 | ML261; ML-261 | Phase 1 Clinical | Moonlight Bio Inc | Carcinoma, Neuroendocrine; Gastroenteropancreatic neuroendocrine tumor; Prostatic Neoplasms; Small Cell Lung Carcinoma | Details |
| NEUK203-13 | NEUK203-13 | Phase 1 Clinical | Neukio Biotherapeutics (Shanghai) Co Ltd | Neuroendocrine Tumors; Small Cell Lung Carcinoma | Details |
| 111In-ABD147 | Phase 1 Clinical | Abdera Therapeutics Inc | Neuroendocrine Tumors; Prostatic Neoplasms, Castration-Resistant; Solid tumours | Details | |
| 111In-ETN029 | 111In-ETN029 | Phase 1 Clinical | Novartis Pharma Ag | Gastroenteropancreatic neuroendocrine tumor; Neuroendocrine Tumors; Prostatic Neoplasms; Small Cell Lung Carcinoma | Details |
| 225Ac-ETN029 | 225Ac-ETN029; [225Ac]Ac-ETN029 | Phase 1 Clinical | Novartis Pharma Ag | Gastroenteropancreatic neuroendocrine tumor; Neuroendocrine Tumors; Prostatic Neoplasms; Small Cell Lung Carcinoma | Details |
| HLX-3901 | HLX-3901 | Phase 1 Clinical | Shanghai Henlius Biotech Inc | Carcinoma, Neuroendocrine; Neoplasm Metastasis; Small Cell Lung Carcinoma; Solid tumours | Details |
| 177Lu-DTPA-SC16.56 | 177Lu-DTPA-SC16.56 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Carcinoma, Neuroendocrine; Lung Neoplasms; Neuroendocrine Carcinoma of Lung; Prostatic Neoplasms | Details |
| SYS-6040 | SYS6040; SYS-6040 | Phase 1 Clinical | Jushi Biopharmaceutical Co Ltd | Neoplasms; Neuroendocrine Tumors; Small Cell Lung Carcinoma; Solid tumours | Details |
| IBI-3009 | IBI3009; IBI-3009 | Phase 1 Clinical | Carcinoma, Neuroendocrine; Small Cell Lung Carcinoma; Solid tumours | Details | |
| BL-M14D1 | BL-M14D1 | Phase 1 Clinical | Baili-Bio (Chengdu) Pharmaceutical Co Ltd, Sichuan Baili Pharmaceutical Co Ltd | Carcinoma, Neuroendocrine; Neuroendocrine Tumors; Small Cell Lung Carcinoma; Solid tumours | Details |
| BHP-01 | BHP-01; BHP01; α-PD-L1/4-1BB DLL3 CAR-T | Phase 1 Clinical | Chengdu Brilliant Pharmaceutical Co Ltd | Small Cell Lung Carcinoma | Details |
| FZ-AD005 | FZ-AD005; FZAD005; F0041 | Phase 1 Clinical | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd | Carcinoma, Neuroendocrine; Glioblastoma; Glioma; Small Cell Lung Carcinoma; Solid tumours | Details |
| [89Zr]Zr-BI-764532 | Phase 1 Clinical | Boehringer Ingelheim International Gmbh, C.H. Boehringer Sohn Ag & Co. Kg | Carcinoma, Neuroendocrine; Small Cell Lung Carcinoma | Details | |
| ABD-147 | ABD-147; 225Ac-ABD147 | Phase 1 Clinical | Abdera Therapeutics Inc | Neuroendocrine Tumors; Small Cell Lung Carcinoma; Solid tumours | Details |
| SNC-115 | SNC115; SNC-115 | Phase 1 Clinical | Shanghai Simnova Biotechnology Co Ltd | Carcinoma, Neuroendocrine; Small Cell Lung Carcinoma; Solid tumours | Details |
| RG-6524 | RO-7616789; ALPS-12; RG6524 | Phase 1 Clinical | F. Hoffmann-La Roche Ag | Carcinoma, Neuroendocrine; Small Cell Lung Carcinoma | Details |
| OBT620 | OBT620 | Phase 1 Clinical | Boehringer Ingelheim Gmbh, Oxford Biotherapeutics Ltd | Small Cell Lung Carcinoma | Details |
| QLS-31904 | QLS-31904; QLS31904 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours | Details |
| LB-2102(Legend Biotechnology) | LB-2102 | Phase 1 Clinical | Neuroendocrine Tumors; Small Cell Lung Carcinoma | Details |
Informations sur les médicaments commercialisés
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Plus ancien nom de marque | Pays d'approbation le plus ancien | Indication la plus ancienne | Société d'approbation la plus ancienne | Date d'approbation la plus ancienne | Indication | Essai clinique |
|---|---|---|---|---|---|---|---|---|---|---|
| Tarlatamab | AMG-757 | Approved | Amgen Inc | Imdelltra | United States | Small Cell Lung Carcinoma | Amgen Inc | 2024-05-16 | Astrocytoma; Brain metastases; Carcinoma, Merkel Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Ganglioglioma; Glioblastoma; Medullary thyroid cancer (MTC); Melanoma; Neoplasms; Neuroendocrine Tumors; Oligodendroglioma; Paranasal Sinus Diseases; Prostatic Neoplasms; Small Cell Lung Carcinoma; Testicular Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | Details |
Avis sur les produits
n***l2026-04-07
1Mettre un likeThe product worked great and was delivered in a timely manner
- Informations sur la molécule
- Liste de produits
- Informations sur les médicaments commercialisés
- Avis sur les produits
- Informations sur les médicaments cliniques